- Aktuelle Seite:
-
Home
-
Substitutionsmittel
- Buprenorphin
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Vierke, C., Marxen, B., Boettcher, M. et al.
Eur Arch Psychiatry Clin Neurosci (2020). doi.org/10.1007/s00406-019-01091-0
https://link.springer.com/article/10.1007%2Fs00406-019-01091-0
Recurrent Use of Implantable Buprenorphine.
Campbell MC.
Prim Care Companion CNS Disord. 2019 Dec 5;21(6). pii: 19l02434. doi: 10.4088/PCC.19l02434.
https://www.psychiatrist.com/pcc/article/pages/2019/v21n06/19l02434.aspx
A Retrospective Survey of Buprenorphine Substitute Treatment With Minimal Dosage in Heroin Use Disorder.
Shen W, Wang Q, Zhang J, Ping W, Zhang J, Ye W, Hu Q, Cerci D, Zhou W.
Front Psychiatry. 2019 Dec 4;10:888. doi: 10.3389/fpsyt.2019.00888.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904327/
Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation.
Ling W, Shoptaw S, Goodman-Meza D.
Subst Abuse Rehabil. 2019 Nov 29;10:69-78. doi: 10.2147/SAR.S155843.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889966/
Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
Weicker SA, Hayashi K, Grant C, Milloy MJ, Wood E, Kerr T.
Drug Alcohol Depend. 2019 Dec 1;205:107672. doi: 10.1016/j.drugalcdep.2019.107672.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31706251
Synthetic Urines in a Buprenorphine Clinic.
Embers DM, Ravishankar DA, Din A, Sethi R.
Kans J Med. 2019 Nov 25;12(4):146-147. eCollection 2019 Nov.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884010/
Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine.
Chhabra N, Aks SE.
Am J Emerg Med. 2019 Nov 16. pii: S0735-6757(19)30627-8. doi: 10.1016/j.ajem.2019.09.014.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31753622
Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine.
Blue TR, Gordon MS, Schwartz RP, Couvillion K, Vocci FJ, Fitzgerald TT, O'Grady KE.
Addict Sci Clin Pract. 2019 Dec 2;14(1):45. doi: 10.1186/s13722-019-0172-2.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886176/
New…and improved? The latest studies on injectable buprenorphine for opioid use disorder
Suboxone is a first-line treatment for opioid use disorder. The need to take it daily, however, increases the risk that someone will miss a dose. Suboxone misuse and diversion also remain prominent concerns. Novel, FDA-approved injection formulations of buprenorphine, the active ingredient in Suboxone, were designed to address these potential drawbacks. Two recent studies show that injection buprenorphine outperforms a placebo injection and does as well as daily sublingual Suboxone. (Recovery Bulletin, USA, Dezember 2019)
https://www.recoveryanswers.org/research-post/monthly-injectable-buprenorphine/
Buprenorphin als Depot – Für stabile und instabile Patienten - Auf Buvidal® einstellen und erfolgreich Rituale aufbrechen
Mannheim/Lund, 4.12.2019 – Seit Februar 2019 können opioidabhängige Patienten*innen in Deutschland mit dem neuen Buprenorphin-Depot Buvidal® behandelt werden. Erfahrungen aus der Praxis zur Ein- und Umstellung auf das Depotpräparat wurden auf einem von der Camurus GmbH unterstützten Satellitensymposium im Rahmen des 28. Kongresses der Deutschen Gesellschaft für Suchtmedizin Anfang November 2019 in Berlin diskutiert. (Camurus, Schweden, Pressemitteilung, 04.12.2019)
Buvidal_Camurus_DGS Symposium Berlin November 2019
Opioid Substitution Treatment Using Buprenorphine for Management of Dependence on Natural Opioids: Case Series.
Kathiresan P, Ambekar A, Sarkar S.
Indian J Psychol Med. 2019 Nov 11;41(6):586-588. doi: 10.4103/IJPSYM.IJPSYM_62_19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875849/
Unusual Drug Test Results for a Patient on Buprenorphine and Naloxone.
Gall B, El-Khoury JM.
Clin Chem. 2019 Oct;65(10):1332-1333. doi: 10.1373/clinchem.2019.309484.
http://clinchem.aaccjnls.org/content/65/10/1332.long
Buprenorphine poisoning in children: a 10-year-experience of Marseille Poison Center.
von Fabeck K, Boulamery A, Glaizal M, de Haro L, Simon N.
Fundam Clin Pharmacol. 2019 Nov 1. doi: 10.1111/fcp.12518.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31675453
A comparison of sexual desire in opiate-dependent men receiving methadone and buprenorphine maintenance treatment.
Yee A, Loh HS, Loh HH, Riahi S, Ng CG, Sulaiman AHB.
Ann Gen Psychiatry. 2019 Oct 22;18:25. doi: 10.1186/s12991-019-0249-z.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805364/
Pharmacoeconomic Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.)
Indication: For the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jul.
https://www.ncbi.nlm.nih.gov/books/NBK546358/
CADTH Canadian Drug Expert Committee Recommendation: Buprenorphine (Sublocade — Indivior Canada Ltd.): Indication: Opioid use disorder [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun.
https://www.ncbi.nlm.nih.gov/books/NBK546256/
Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study.
Murnion BP, Rivas C, Demirkol A, Hayes V, Lintzeris N, Nielsen S.
Pain Med. 2019 Aug 24. pii: pnz178. doi: 10.1093/pm/pnz178.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31504868
Anästhesievorbereitung: Welche Medikamente vor einer Narkose abgesetzt werden sollten
Schreiner, Mathias J.; Kehl, Franz
Dtsch Arztebl 2019; 116(31-32): A-1428 / B-1183 / C-1167
What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.
Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A, Brousse G, Jamain T, Kosim M, Rolland B.
Expert Opin Drug Deliv. 2019 Sep;16(9):907-914. doi: 10.1080/17425247.2019.1649252.
https://www.tandfonline.com/doi/full/10.1080/17425247.2019.1649252
Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution
Soyka, M. & Pogarell, O.
Nervenarzt (2019) 90: 932. doi.org/10.1007/s00115-019-0783-6
Abstract
https://link.springer.com/article/10.1007%2Fs00115-019-0783-6
Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines [Internet].
Edge R, Butcher R.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May 9. PMID: 31479216
https://www.ncbi.nlm.nih.gov/books/NBK545816/
Auf der Packungsrückseite: Falsche Wirkstoffgehaltsangabe bei Subutex
Die Firma Indivior ruft eine Charge Subutex 8mg Sublingualtabletten 28 Stück zurück. Der Grund: Auf der Rückseite der Packung ist der falsche Wirkstoffgehalt aufgedruckt. (Deutsche Apotheker Zeitung, 05.09.2019)
Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.
Withey SL, Spealman RD, Bergman J, Paronis CA.
J Pharmacol Exp Ther. 2019 Aug 14. pii: jpet.119.259010. doi: 10.1124/jpet.119.259010
http://jpet.aspetjournals.org/content/early/2019/08/14/jpet.119.259010.long
Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine .
Strang J, Knight A, Baillie S, Reed K, Bogdanowicz K, Bell J.
Int J Clin Pharmacol Ther. 2018 Feb;56(2):81-85. doi: 10.5414/CP203118.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/29231163
SUBOXONE® (buprenorphine and naloxone) sublingualfilm CIII – RISK EVALUATION AND MITIGATION STRATEGY (REMS)
Buprenorphine (opioid partial agonist‐antagonist) Naloxone (opioidantagonist)
Initial REMS approval: 08/2010, Most recent modification: 04/2014 NDA 22‐410
Reckitt Benckiser Pharmaceuticals Inc.
https://www.fda.gov/media/79068/download
Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
Wachman EM, Saia K, Miller M, Valle E, Shrestha H, Carter G, Werler M, Jones H.
Clin Ther. 2019 Jul 27. pii: S0149-2918(19)30346-7. doi: 10.1016/j.clinthera.2019.07.003.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31358302
Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
Chilcoat HD, Amick HR, Sherwood MR, Dunn KE.
J Subst Abuse Treat. 2019 Sep;104:148-157. doi: 10.1016/j.jsat.2019.07.005.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31370979
Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol.
Terasaki D, Smith C, Calcaterra SL.
Pharmacotherapy. 2019 Jul 26. doi: 10.1002/phar.2313.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31348544
Successful Treatment of Opioid Dependence with Flexible Doses of Injectable Prolonged Release Buprenorphine.
Oscar D’Agnone
Case Reports in Psychiatry, vol. 2019, Article ID 9381346, 4 pages, 2019. doi.org/10.1155/2019/9381346.
https://www.hindawi.com/journals/crips/2019/9381346
Meta-Opinion. What place for prolonged-release buprenorphine depot formulations (Buvidal®) in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.
Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A, Brousse G, Jamain T, Kosim M, Rolland B.
Expert Opin Drug Deliv. 2019 Jul 31. doi: 10.1080/17425247.2019.1649252.
https://www.tandfonline.com/doi/full/10.1080/17425247.2019.1649252
Seite 1 von 9